Tags

Type your tag names separated by a space and hit enter

Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy.
Rev Rhum Engl Ed. 1997 Jul-Sep; 64(7-9):451-8.RR

Abstract

OBJECTIVES

To study bone mass and the factors that influence bone mass in rheumatoid arthritis patients versus controls.

PATIENTS AND METHODS

85 patients (73 women) with a mean age of 57 +/- 11 years and a mean disease duration of 13 +/- 9 years were compared to 85 age- and sex-matched controls. Among the patients, 62 (76%) had positive rheumatoid factor tests and 51 (60%) were receiving steroid therapy, with a mean daily dose of 10 +/- 4 mg and a mean duration of 7 +/- 6 years. The following parameters were determined: morning stiffness duration, painful and swollen joint counts, Lee's and Ritchie's indices, Health Assessment Questionnaire score, erythrocyte sedimentation rate, and C-reactive protein. Bone mineral density was measured at the lumbar spine and femoral neck using dual-energy X-ray absorptiometry (Sophos L-XRA).

RESULTS

In the nonsteroid-treated patients, bone mineral density was similar to that in controls at the lumbar spine but was decreased by 8% (95% confidence interval [CI], 1.8-14.2%) at the femoral neck (0.76 +/- 0.14 g/cm2 versus 0.83 +/- 0.15 g/cm2; P = 0.03). Decreases of 11.5% (95% CI, 8.1-14.9%) at the lumbar spine and 10.4% (95% CI, 6.4-14.4%) at the femoral neck were found in the steroid-treated patients versus the nonsteroid-treated patients. In the patient group, femoral neck bone mineral density was significantly negatively correlated with age (r = -0.5), the Heath Assessment Questionnaire score (r = -0.27), and the erythrocyte sedimentation rate (r = -0.25), whereas only the first two variables were significantly correlated with lumbar bone mineral density. A multiple linear regression model including age, glucocorticoid use, rheumatoid factor, the Health Assessment Questionnaire score, and the erythrocyte sedimentation rate was constructed and adjusted for the number of variables. This model explained 44.7% of the variance of femoral neck bone mineral density.

CONCLUSION

Rheumatoid arthritis is associated with a decrease in bone mass that is most marked in patients with active and/or severe disease and in those who take glucocorticoids.

Authors+Show Affiliations

Rheumatology Department, Lille Teaching Hospital, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

9338926

Citation

Cortet, B, et al. "Evaluation of Bone Mineral Density in Patients With Rheumatoid Arthritis. Influence of Disease Activity and Glucocorticoid Therapy." Revue Du Rhumatisme (English Ed.), vol. 64, no. 7-9, 1997, pp. 451-8.
Cortet B, Flipo RM, Blanckaert F, et al. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed. 1997;64(7-9):451-8.
Cortet, B., Flipo, R. M., Blanckaert, F., Duquesnoy, B., Marchandise, X., & Delcambre, B. (1997). Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Revue Du Rhumatisme (English Ed.), 64(7-9), 451-8.
Cortet B, et al. Evaluation of Bone Mineral Density in Patients With Rheumatoid Arthritis. Influence of Disease Activity and Glucocorticoid Therapy. Rev Rhum Engl Ed. 1997 Jul-Sep;64(7-9):451-8. PubMed PMID: 9338926.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. AU - Cortet,B, AU - Flipo,R M, AU - Blanckaert,F, AU - Duquesnoy,B, AU - Marchandise,X, AU - Delcambre,B, PY - 1997/7/1/pubmed PY - 1997/10/27/medline PY - 1997/7/1/entrez SP - 451 EP - 8 JF - Revue du rhumatisme (English ed.) JO - Rev Rhum Engl Ed VL - 64 IS - 7-9 N2 - OBJECTIVES: To study bone mass and the factors that influence bone mass in rheumatoid arthritis patients versus controls. PATIENTS AND METHODS: 85 patients (73 women) with a mean age of 57 +/- 11 years and a mean disease duration of 13 +/- 9 years were compared to 85 age- and sex-matched controls. Among the patients, 62 (76%) had positive rheumatoid factor tests and 51 (60%) were receiving steroid therapy, with a mean daily dose of 10 +/- 4 mg and a mean duration of 7 +/- 6 years. The following parameters were determined: morning stiffness duration, painful and swollen joint counts, Lee's and Ritchie's indices, Health Assessment Questionnaire score, erythrocyte sedimentation rate, and C-reactive protein. Bone mineral density was measured at the lumbar spine and femoral neck using dual-energy X-ray absorptiometry (Sophos L-XRA). RESULTS: In the nonsteroid-treated patients, bone mineral density was similar to that in controls at the lumbar spine but was decreased by 8% (95% confidence interval [CI], 1.8-14.2%) at the femoral neck (0.76 +/- 0.14 g/cm2 versus 0.83 +/- 0.15 g/cm2; P = 0.03). Decreases of 11.5% (95% CI, 8.1-14.9%) at the lumbar spine and 10.4% (95% CI, 6.4-14.4%) at the femoral neck were found in the steroid-treated patients versus the nonsteroid-treated patients. In the patient group, femoral neck bone mineral density was significantly negatively correlated with age (r = -0.5), the Heath Assessment Questionnaire score (r = -0.27), and the erythrocyte sedimentation rate (r = -0.25), whereas only the first two variables were significantly correlated with lumbar bone mineral density. A multiple linear regression model including age, glucocorticoid use, rheumatoid factor, the Health Assessment Questionnaire score, and the erythrocyte sedimentation rate was constructed and adjusted for the number of variables. This model explained 44.7% of the variance of femoral neck bone mineral density. CONCLUSION: Rheumatoid arthritis is associated with a decrease in bone mass that is most marked in patients with active and/or severe disease and in those who take glucocorticoids. SN - 1169-8446 UR - https://www.unboundmedicine.com/medline/citation/9338926/Evaluation_of_bone_mineral_density_in_patients_with_rheumatoid_arthritis__Influence_of_disease_activity_and_glucocorticoid_therapy_ L2 - http://www.diseaseinfosearch.org/result/592 DB - PRIME DP - Unbound Medicine ER -